## DKN-01 and tislelizumab as a second-line (2L) investigational therapy in advanced DKK1 high gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial

Samuel J. Klempner<sup>a</sup>, Jaffer A. Ajani<sup>b</sup>, Joseph Chao<sup>c</sup>, Hope Uronis<sup>d</sup>, Cynthia A. Sirard<sup>e</sup>, Michael Kagey<sup>e</sup>, Jason Baum<sup>e</sup>, Lilin Zhang<sup>f</sup>, In-Ho Kim<sup>g</sup>, Do-Youn Oh<sup>h</sup>, Byoung Yong Shim<sup>i</sup>, Sun Jin Sym<sup>j</sup>; Mohamad Sonbol<sup>k</sup>, Mohamedtaki A. Tejani<sup>l</sup>, Zev Wainberg<sup>m</sup>, Devalingam Mahalingam<sup>n</sup>, Keun-Wook Lee<sup>o</sup> - Massachusetts General Hospital Cancer Center; Boston, MA<sup>a</sup>; MD Anderson Cancer Center, Houston, TX<sup>b</sup>; City of Hope Comprehensive Cancer Center, Duarte, CA<sup>c</sup>; Duke University Medical Center, Durham, NC<sup>d</sup>, Leap Therapeutics, Cambridge, MA<sup>e</sup>; BeiGene, Ltd, Beijing, China<sup>f</sup>; Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea<sup>g</sup>; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea<sup>h</sup>; The Catholic University of Korea St. Vincent's Hospital, Suwon, South Korea<sup>i</sup>; Gachon University Gil Medical Center, Incheon, South Korea<sup>j</sup>; Mayo Clinic Hospital, Phoenix, AZ<sup>k</sup>; AdventHealth Cancer Institute, Orlando, FL<sup>l</sup>; University of California Los Angeles, Los Angeles, CA<sup>m</sup>; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL<sup>n</sup>; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul National University College of Medicine, Seoul National University College of California Los Angeles, Los Angeles, CA<sup>m</sup>; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL<sup>n</sup>; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul National University College

**Background:** Elevated tumoral DKK1 expression is seen in approximately one third of previously treated GEA and has been associated with more aggressive disease and shorter overall survival. DKN-01 (D) is a targeted anti-DKK1 mAb which has demonstrated improved clinical outcomes in previously treated GEA pts with elevated tumoral DKK1 expression when used in combination with an anti-PD1 antibody.

**Methods:** DisTinGuish (NCT04363801) is a Phase 2a single arm 2-part trial; Part A is reported separately; Part B investigated two dosing cohorts of D (300 mg and 600 mg) + tislelizumab (TS) as 2L therapy for DKK1-high GEA pts. Primary objective was to examine safety and tolerability and secondary objectives evaluated multiple efficacy endpoints including overall response rate (ORR) and disease control rate (DCR) in a modified intent to treat (mITT) population (>1 dose D).

**Results:** 52 pts enrolled between 27 Oct 2020 and 7 Jun 2022; (D-300 mg, 24 pts; D-600 mg 28 pts). Median age was 63 (29, 76); 41 males (79%). 18 pts (35%) had gastroesophageal junction (GEJ) adenocarcinoma; 34 pts (65%) had gastric cancer (GC). 22 pts from US, 30 pts from Republic of Korea. 49 pts have PD-L1 visually-estimated combined positive score (vCPS) results: <1 n=13 (27%); 1-<10 n=22 (45%); ≥10 n=14 (29%). 38 pts with genomic profiling: Wnt activating mutations in 12 pts, no MSI-H. 4 pts were IO experienced. Median number of cycles 2 (1, 19). 12 pts remain on therapy. 19 pts (37%) experienced D-related adverse events (AE); 74% were G1/2. Most common regimen related AEs: fatigue, nausea, AST increased. 3 pts (6%) had serious D-related AEs [vomiting, fatigue, dehydration]. No G5 TRAEs. No D-related AE led to D-dose reduction or discontinuation. Preliminary ORR in response evaluable IO naive mITT (n=36) was 25% and DCR 44%. mITT ORR by vCPS (Figure 1): <1: [n=11; PR-3 (27%), SD-1, PD-7]; 1-<10: [n=12; PR-1 (8%), SD-3, PD-8 (1 PD pt -> irPR)]; ≥10: [n=11; PR-5 (45%), SD-3, PD-3]. 6 of 9 responders remain on therapy, median DoR not reached. Median PFS: 1.4 mos (vCPS <1: 1.4 mos, 1-<10: 1.4 mos, ≥10: 2.9 mos).

**Conclusions:** The combination of D + TS represents a well-tolerated, active chemotherapy-free combination in previously treated DKK1-high IO naïve GEA pts. Encouraging durable activity was observed particularly in DKK1 high/vCPS≥10 cohort: ORR 45%, DCR 73%. Updated ORR, DoR, PFS and additional correlative biomarker evaluation will be reported.




Figure 1.

Based on data as of 30Jun2022